Comparative Pharmacology
Head-to-head clinical analysis: KARBINAL ER versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARBINAL ER versus PROMETHAZINE DM.
KARBINAL ER vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine is a first-generation antihistamine with anticholinergic and sedative properties. It competitively antagonizes histamine at H1 receptor sites, thereby alleviating symptoms of allergic reactions.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Adults: 1-2 tablets (6-12 mg carbinoxamine) orally every 4-6 hours as needed; maximum 24 mg/day.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life ranges from 20 to 30 hours, supporting once-daily dosing in extended-release formulation.
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal (approximately 50% as unchanged drug and metabolites); fecal (approximately 40%); biliary (minor).
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic